TSEC:4142

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Adimmune Corporation manufactures and sells human vaccines in Taiwan. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Adimmune's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4142 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 4142's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

1.6%

4142

-2.3%

TW Biotechs

-0.2%

TW Market


1 Year Return

103.2%

4142

21.7%

TW Biotechs

28.6%

TW Market

Return vs Industry: 4142 exceeded the TW Biotechs industry which returned 21.7% over the past year.

Return vs Market: 4142 exceeded the TW Market which returned 28.6% over the past year.


Shareholder returns

4142IndustryMarket
7 Day1.6%-2.3%-0.2%
30 Day-15.3%-7.8%8.8%
90 Day-25.1%-2.8%20.6%
1 Year103.2%103.2%22.2%21.7%33.1%28.6%
3 Year153.0%153.0%-17.7%-19.2%55.3%37.8%
5 Year133.9%133.9%-48.1%-48.6%135.7%94.2%

Long-Term Price Volatility Vs. Market

How volatile is Adimmune's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Adimmune undervalued compared to its fair value and its price relative to the market?

4.35x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4142's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4142's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4142 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 4142 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4142's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4142 is good value based on its PB Ratio (4.4x) compared to the TW Biotechs industry average (4.8x).


Next Steps

Future Growth

How is Adimmune forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

86.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Adimmune has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Adimmune performed over the past 5 years?

19.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4142 is currently unprofitable.

Growing Profit Margin: 4142 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4142 is unprofitable, but has reduced losses over the past 5 years at a rate of 19.7% per year.

Accelerating Growth: Unable to compare 4142's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4142 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).


Return on Equity

High ROE: 4142 has a negative Return on Equity (-1.16%), as it is currently unprofitable.


Next Steps

Financial Health

How is Adimmune's financial position?


Financial Position Analysis

Short Term Liabilities: 4142's short term assets (NT$3.6B) exceed its short term liabilities (NT$404.8M).

Long Term Liabilities: 4142's short term assets (NT$3.6B) exceed its long term liabilities (NT$1.0B).


Debt to Equity History and Analysis

Debt Level: 4142's debt to equity ratio (20.8%) is considered satisfactory.

Reducing Debt: 4142's debt to equity ratio has reduced from 37.5% to 20.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4142 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4142 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 11.2% each year


Next Steps

Dividend

What is Adimmune current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4142's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4142's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4142's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4142's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4142's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.6yrs

Average management tenure


CEO

Qi Xian Zhan

12.5yrs

Tenure

Qi Xian Zhan has been Chief Executive Officer of Adimmune Corporation since July 01, 2008 and serves as its Chairman of the Board of Directors. Qi Xian Zhan served as President at Chi Mei Hospital. Qi Xian...


Leadership Team

NamePositionTenureCompensationOwnership
Qi Xian Zhan
Chairman of the Board of Directors and Chief Executive Officer12.5yrsno data0.79%
NT$ 178.0m
Zhe Wei Zhang
Chief Financial Officer and Directorno datano datano data
Jin Quan Zhang
Chief Operating Officer16.17yrsno data0.000020%
NT$ 4.5k
Jing Yao Lin
Administrative Center Director9.5yrsno datano data
Fei Pan
Legal Counsel8.83yrsno datano data
Shengkai Gao
Deputy General Managerno datano data0.14%
NT$ 32.0m

11.6yrs

Average Tenure

Experienced Management: 4142's management team is seasoned and experienced (11.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.4%.


Top Shareholders

Company Information

Adimmune Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Adimmune Corporation
  • Ticker: 4142
  • Exchange: TSEC
  • Founded: 1965
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$22.463b
  • Shares outstanding: 429.51m
  • Website: https://www.adimmune.com.tw

Number of Employees


Location

  • Adimmune Corporation
  • No. 389, Xiangshun Rd
  • Sec. 2
  • Taichung
  • 409
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4142TSEC (Taiwan Stock Exchange)YesCommon StockTWTWDSep 2010

Biography

Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, an influenza vaccine; tetanus toxoid alum precipitated products used for prevention of tetanus after injury; Japan...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 08:39
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.